Publikationsverzeichnis PD Dr. med. Martin Salzmann

Erst-Autorschaften

• Salzmann, M.; Leiter, U.; Loquai, C.; Zimmer, L.; Ugurel, S.; Gutzmer, R.; Thoms, K.M.; Enk, A.H.; Hassel, J.C.: Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. European Journal of Cancer (Oxford, England: 1990) 2020, 138, 125-132
• Salzmann, M.; Benesova, K.; Buder-Bakhaya, K.; Papamichail, D.; Dimitrakopoulou-Strauss, A.; Lorenz, H.M.; Enk, A.H.; Hassel, J.C.: Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients. Cancers 2020, 12:3004
• Salzmann, M.; Tosev, G.; Heck, M.; Schadendorf, D.; Maatouk, I.; Enk, A.H.; Hartmann, M.; Hassel, J.C.: Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study. European Journal of Cancer (Oxford, England: 1990) 2021, 152, 41-48
• Salzmann, M.; Pawlowski, J.; Loquai, C.; Rafei-Shamsabadi, D.A.; Meiss, F.; Ugurel, S.; Schadendorf, D.; Meier, F.; Enk, A.H.; Hassel, J.C.: MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study. European Journal of Cancer (Oxford, England: 1990) 2022, 166, 24-32
• Salzmann M.; Wald, A.; Stege, H.; Loquai, C.; Zimmer, L.; Hayani, K.M.; Heinzerling, L.; Gutzmer, R.; Enk, A.H.; Hassel, J.C.: Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study. Cancers 2023,15(5):1426
• Salzmann, M.; Hess, K.; Lang, K.; Enk, A.H.; Jordan, B.; Hassel, J.C.: Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy. Strahlentherapie und Onkologie 2022, 198(10): 884-891
• Salzmann, M.; Enk, A.H.; Hassel, J.C.: S100 as Serum Tumor Marker in Uveal Melanoma. Biomolecules 2023, 13(3), 529 
• Salzmann, M.; Marmé, F.; Hassel, J.C.: Prophylaxis and Management of Skin Toxicities. Breast Care (Basel, Switzerland) 2019, 14, 72-77
• Salzmann, M.; Hassel, J.C.: Checkpoint-Inhibitoren zur Behandlung des fortgeschrittenen Melanoms: Grundlagen und Nebenwirkungen [CME-Fortbildung]. HAUT 06/2020: 282-287
• Salzmann, M.*; Rendon, A.*; Toberer, F.; Hassel, J.C.: Generalized perforating granuloma annulare: a case report. Journal der Deutschen Dermatologischen Gesellschaft: JDDG 2021, 19, 585-587
• Dietrich, C.*; Salzmann, M.*; Steinbrecher, A.; Herbst, R.; Hassel, J.C.: Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumab. Immunotherapy 2021, 13, 1079-1083
• Dietrich, C.*; Salzmann, M.*; Streit, E.; Toberer, F.; Emmert, S.; Dikow, N.; Haenssle, H.: Novel pathogenic frameshift mutation in the POLH gene contributes to xeroderma pigmentosum variant type in a 16-year-old girl. Australasian Journal of Dermatology 2021, 62, E615-E617
• Salzmann, M.; Löser, C.; Hassel, J.C.: Divergent response to PD-L1 inhibition in advanced merkel cell carcinoma and cutaneous squamous cell carcinoma. Journal der Deutschen Dermatologischen Gesellschaft: JDDG 2023, 21 (7): 803-805
• Salzmann M., Hassel J.C., Höller U.: Skin Care During and After Radiotherapy and Anticancer Treatment. Buchbeitrag in: Wenz F. (eds) Radiation Oncology. Springer, Cham. doi:10.1007/978-3-319-52619-5_115-1 

Co-Autorschaften:

• Kramer, R.; Zaremba, A.; Moreira, A.; Ugurel, S.; Johnson, D.B.; Hassel, J.C.; Salzmann, M.; Gesierich, A.; Weppler, A.; Spain, L.; Loquai, C.; Dudda, M.; Pföhler, C.; Hepner, A.; Long, G. V.; Menzies, A. M.; Carlino, M. S.; Sachse, M. M.; Lebbé, C.; Baroudjian, B.; Enokida, T.; Tahara, M.; Schlaak, M.; Hayani, K.; Bröckelmann, P. J.; Meier, F.; Reinhardt, L.; Friedlander, P.; Eigentler, T.; Kähler, K. C.; Berking, C.; Zimmer, L.; Heinzerling, L.: Hematological immune related adverse events after treatment with immune checkpoint inhibitors. European Journal of Cancer (Oxford, England: 1990) 2021, 147, 170-181
•  Zaremba, A.; Kramer, R.; De Temple, V.; Bertram, S.; Salzmann, M.; Gesierich, A.; Reinhardt, L.; Baroudjian, B.; Sachse, M.M.; Mechtersheimer, G.; Johnson, D. B.; Weppler, A. M.; Spain, L.; Loquai, C.; Dudda, M.; Pföhler, C.; Hepner, A.; Long, G. V.; Menzies, A. M.; Carlino, M. S.; Lebbé, C.; Enokida, T.; Tahara, M.; Bröckelmann, P. J.; Eigentler, T.; Kähler, K. C.; Gutzmer, R.; Berking, C.; Ugurel, S.; Stadtler, N.; Sucker, A.; Becker, J. C.; Livingstone, E.; Meier, F.; Hassel, J. C.; Schadendorf, D.; Hanoun, M.; Heinzerling, L.; Zimmer, L.: Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis. Frontiers in Oncology 2021, 11, 765608
• Hassel, J.C.; Schank, T.E.; Smetak, H.; Mühlbauer, J.; Salzmann, M.; Machiraju, D.; Menzer, C.; Lang, K.; König, L.; Haefner, M.F.; Hülsmeyer, I.; Kohler, C.; Spang, R.; Enk, A.; Debus, J.; Beckhove, P: Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA). Oncoimmunology 2022, 11, 2066609
• Müller-Jensen, L.; Zierold, S.; Versluis, J.M.; Boehmerle, W.; Huehnchen, P.; Endres, M.; Mohr, R.; Compter, A.; Blank, C.U.; Hagenacker, T.; Meier, F.; Reinhardt, L.; Gesierich, A.; Salzmann, M.; Hassel, J.C.; Ugurel, S.; Zimmer, L.; Banks, P.; Spain, L.; Soon, J.A.; Enokida, T.; Tahara, M.; Kähler, K.C.; Seggewiss-Bernhardt, R.; Harvey, C.; Long, G.V.; Schöberl, F.; von Baumgarten, L.; Hundsberger, T.; Schlaak, M.; French, L.E.; Knauss, S.; Heinzerling, L.M.: Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. European Journal of Cancer 175: 224-235
• Haist, M.; Stege, H.; Lang, B.M.; Tsochataridou, A.; Salzmann, M.; Mohr, P.; Schadendorf, D.; Ugurel, S.; Placke, J.M.; Weichenthal, M.; Gutzmer, R.; Leiter, U.; Kaatz, M.; Haferkamp, S.; Berking, C.; Heppt, M.; Tschechne, B.; Schummer, P.; Gebhardt, C.; Grabbe, S.; Loquai, C.: Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry. Cancers (Basel) 2022: 14(22)
• Salzmann, S.; Salzmann, M.; Staubach, P. Compounded preparations in dermatology - analysis of prescribing habits in everyday clinical practice in Germany. Journal der Deutschen Dermatologischen Gesellschaft: JDDG 2020, 18, 334-340
• Steeb, T.; Wessely, A.; Drexler, K.; Salzmann, M.; Toussaint, F.; Heinzerling, L.; Reinholz, M.; Berking, C.; Heppt, M.V.: The Quality of Practice Guidelines for Melanoma: A Methodologic Appraisal with the AGREE II and AGREE-REX Instruments. Cancers 2020, 12
• Grabbe, P.; Gschwendtner, K.M.; Maatouk, I.; Strobel, S.B.; Salzmann, M.; Bossert, J.; Eich, W.; Wild, B.; Meier, F.; Hassel, J.C.; Bieber C.: Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial. Trials 2021, 22, 294
• Zhang, X. W.; Wald A.; Salzmann M.; Halama N.; Hassel J.C.: Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma. Cancer Immunology Immunotherapy 2023 Feb; 72(2):509-513
• Müller-Jensen, L.; Zierold, S.; Versluis, J.M.; Boehmerle, W.; Huehnchen, P.; Endres, M.; Mohr, R.; Compter, A.; Blank, C.U.; Hagenacker, T.; Meier, F.; Reinhardt, L.; Gesierich, A.; Salzmann, M.; Hassel, J.C.; Ugurel, S.; Zimmer, L.; Banks, P.; Spain, L.; Soon, J.A.; Enokida, T.; Tahara, M.; Kähler, K.C.; Seggewiss-Bernhardt, R.; Harvey, C.; Long, G.V.; Schöberl, F.; von Baumgarten, L.; Hundsberger, T.; Schlaak, M.; French, L.E.; Knauss, S.; Heinzerling, L.M.: Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis. Data in Brief 2022, 45: 108649